Raymond James & Associates Biogen Inc. Transaction History

Raymond James & Associates

$161 Billion
Q3 2024

A detailed history of Raymond James & Associates transactions in Biogen Inc. stock. As of the latest transaction made, Raymond James & Associates holds 192,065 shares of BIIB stock, worth $28.1 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

192,065

Previous 185,681 3.44%

Holding current value

$28.1 Million

Previous $43 Million 13.51%

% of portfolio

0.02%

Previous 0.03%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 18, 2024	BUY	$189.07 - $236.8 $1.21 Million - $1.51 Million	6,384 Added 3.44%	192,065 $37.2 Million
Q2 2024 Jul 19, 2024	BUY	$190.52 - $236.72 $3.34 Million - $4.16 Million	17,557 Added 10.44%	185,681 $43 Million
Q1 2024 Apr 22, 2024	BUY	$212.02 - $267.71 $5.52 Million - $6.97 Million	26,048 Added 18.33%	168,124 $36.3 Million
Q4 2023 Jan 16, 2024	SELL	$222.59 - $267.94 $2.27 Million - $2.73 Million	-10,184 Reduced 6.69%	142,076 $36.8 Million
Q3 2023 Oct 24, 2023	BUY	$253.3 - $285.89 $2.03 Million - $2.3 Million	8,029 Added 5.57%	152,260 $39.1 Million
Q2 2023 Jul 25, 2023	BUY	$275.25 - $318.06 $6.55 Million - $7.57 Million	23,814 Added 19.78%	144,231 $41.1 Million
Q1 2023 Apr 14, 2023	SELL	$256.56 - $292.34 $273,749 - $311,926	-1,067 Reduced 0.88%	120,417 $33.5 Million
Q4 2022 Feb 08, 2023	SELL	$252.44 - $306.72 $822,701 - $999,600	-3,259 Reduced 2.61%	121,484 $33.6 Million
Q3 2022 Oct 25, 2022	SELL	$194.69 - $268.46 $452,264 - $623,632	-2,323 Reduced 1.83%	124,743 $33.3 Million
Q2 2022 Aug 12, 2022	SELL	$187.54 - $223.02 $1.82 Million - $2.16 Million	-9,696 Reduced 7.09%	127,066 $25.9 Million
Q1 2022 May 11, 2022	BUY	$193.77 - $244.14 $868,089 - $1.09 Million	4,480 Added 3.39%	136,762 $28.8 Million
Q4 2021 Feb 08, 2022	SELL	$223.92 - $287.77 $4.19 Million - $5.38 Million	-18,700 Reduced 12.39%	132,282 $31.7 Million
Q3 2021 Nov 02, 2021	BUY	$282.99 - $369.05 $3.83 Million - $5 Million	13,546 Added 9.86%	150,982 $42.7 Million
Q2 2021 Aug 11, 2021	SELL	$259.0 - $414.71 $634,032 - $1.02 Million	-2,448 Reduced 1.75%	137,436 $47.6 Million
Q1 2021 May 14, 2021	SELL	$242.95 - $284.63 $258,741 - $303,130	-1,065 Reduced 0.76%	139,884 $39.1 Million
Q4 2020 Feb 12, 2021	SELL	$236.26 - $355.63 $2.34 Million - $3.53 Million	-9,913 Reduced 6.57%	140,949 $34.5 Million
Q3 2020 Nov 04, 2020	SELL	$264.77 - $305.71 $4.09 Million - $4.72 Million	-15,432 Reduced 9.28%	150,862 $42.8 Million
Q2 2020 Jul 28, 2020	SELL	$258.66 - $342.55 $2.82 Million - $3.73 Million	-10,902 Reduced 6.15%	166,294 $44.5 Million
Q1 2020 Apr 21, 2020	SELL	$268.85 - $341.04 $43 Million - $54.6 Million	-159,964 Reduced 47.44%	177,196 $56.1 Million
Q4 2019 Feb 12, 2020	SELL	$220.06 - $304.07 $7.76 Million - $10.7 Million	-35,266 Reduced 9.47%	337,160 $100 Million
Q3 2019 Nov 07, 2019	SELL	$217.44 - $243.88 $665,366 - $746,272	-3,060 Reduced 0.81%	372,426 $86.7 Million
Q2 2019 Aug 06, 2019	SELL	$219.29 - $241.72 $9.77 Million - $10.8 Million	-44,543 Reduced 10.6%	375,486 $87.8 Million
Q1 2019 May 06, 2019	BUY	$216.71 - $338.96 $2.96 Million - $4.63 Million	13,645 Added 3.36%	420,029 $99.3 Million
Q4 2018 Feb 11, 2019	SELL	$278.5 - $352.75 $4.22 Million - $5.35 Million	-15,168 Reduced 3.6%	406,384 $122 Million
Q3 2018 Nov 14, 2018	BUY	$293.51 - $383.83 $614,903 - $804,123	2,095 Added 0.5%	421,552 $149 Million
Q2 2018 Aug 14, 2018	BUY	$257.52 - $306.91 $20.7 Million - $24.6 Million	80,296 Added 23.67%	419,457 $122 Million
Q1 2018 May 14, 2018	BUY	$260.13 - $367.91 $1.01 Million - $1.42 Million	3,866 Added 1.15%	339,161 $92.9 Million
Q4 2017 Feb 14, 2018	BUY	$307.64 - $344.58 $801,094 - $897,286	2,604 Added 0.78%	335,295 $107 Million
Q3 2017 Nov 13, 2017	BUY	$281.15 - $329.69 $2.42 Million - $2.84 Million	8,622 Added 2.66%	332,691 $104 Million
Q2 2017 Aug 14, 2017	BUY	N/A	324,069	324,069 $87.9 Million

Others Institutions Holding BIIB

# of Institutions

1,037

Shares Held

126M

Call Options Held

1.13M

Put Options Held

1.43M

View Full List

About BIOGEN INC.

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $21.1B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

More about BIIB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.

Account

Raymond James & Associates Biogen Inc. Transaction History